Syneos Health (SYNH) Upgraded at Zacks Investment Research
Zacks Investment Research upgraded shares of Syneos Health (NASDAQ:SYNH) from a hold rating to a buy rating in a research report report published on Tuesday morning. They currently have $58.00 price target on the stock.
According to Zacks, “INC Research Holdings, Inc. is a global contract research organization. It provides the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, regulatory and medical writing, and functional service; and data services consisting of clinical data management, electronic data capture, and biostatistics. INC Research Holdings, Inc. is headquartered in Raleigh, North Carolina. “
Several other equities research analysts also recently weighed in on the stock. ValuEngine downgraded shares of Syneos Health from a hold rating to a sell rating in a research report on Thursday, September 6th. Evercore ISI started coverage on shares of Syneos Health in a report on Thursday, October 4th. They issued an outperform rating and a $58.00 price target for the company. KeyCorp lifted their price target on shares of Syneos Health from $54.00 to $59.00 and gave the company an overweight rating in a report on Friday, August 10th. UBS Group started coverage on shares of Syneos Health in a report on Tuesday, October 9th. They issued a buy rating and a $60.00 price target for the company. Finally, Mizuho reaffirmed a hold rating and issued a $51.00 price target on shares of Syneos Health in a report on Monday, August 6th. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Syneos Health has an average rating of Buy and a consensus target price of $54.90.
Syneos Health (NASDAQ:SYNH) last released its earnings results on Tuesday, November 6th. The company reported $0.75 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.58 by $0.17. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.12 billion. Syneos Health had a negative net margin of 0.84% and a positive return on equity of 8.67%. The business’s revenue was up 88.3% compared to the same quarter last year. On average, equities analysts expect that Syneos Health will post 2.47 EPS for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. First Manhattan Co. acquired a new position in shares of Syneos Health in the 3rd quarter valued at about $103,000. First Trust Advisors LP acquired a new position in Syneos Health during the 2nd quarter valued at about $241,000. Crossmark Global Holdings Inc. acquired a new position in Syneos Health during the 2nd quarter valued at about $246,000. Janney Montgomery Scott LLC acquired a new position in Syneos Health during the 2nd quarter valued at about $252,000. Finally, Campbell & CO Investment Adviser LLC acquired a new position in Syneos Health during the 3rd quarter valued at about $294,000.
Syneos Health Company Profile
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Read More: Understanding Analyst Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.